Seaport Therapeutics, Inc. Common Stock

PureTech Health PLC reported H1 2026 cash and short-term investments of $220 million, down from $277.1 million at year-end 2025, providing operational runway at least through the end of 2028. Seaport Therapeutics completed a successful IPO on NASDAQ, raising $260 million, while Gallup Oncology received FDA Fast Track designation for LYT200 in relapsed/refractory high-risk MDS and completed a successful End of Phase 1 meeting. Estimated future proceeds from Cobenfy royalties and milestones were materially downgraded to approximately $50 million based on analyst consensus. PureTech reserved $70 million for future investment in Celia Therapeutics, which will require additional financing to complete its Phase 3 trial, and expects go-forward cash burn of $30 million to $40 million a year, down from roughly $90 million when later-stage clinical programs were run internally. Gallup Oncology's Phase 2 STRIDE MDS trial is not expected to be pivotal and will take approximately 30 to 33 months, with initiation contingent on external financing targeted for completion by the first half of next year.

Seaport Therapeutics has emerged as a potential acquisition target for major pharmaceutical companies following its May 2026 IPO. The company's Glyph prodrug platform has generated 24 candidates, with lead asset GlyphAllo entering Phase 2b for major depressive disorder and topline results expected in the first half of 2027. Bristol Myers Squibb, which previously paid $14 billion for Karuna Therapeutics co-founded by Seaport CEO Daphne Zohar, is ranked as the top potential acquirer. Johnson & Johnson, AbbVie, and Sanofi are also named as plausible buyers. Seaport completed an upsized $260 million IPO and holds $427.26 million in cash, guiding to a runway into 2029.